UTR-TEAD1

UTR-TEAD1 is an investigational RNA-based therapeutic developed by UTR Therapeutics. It utilizes a proprietary RNA rewriting platform that employs engineered destabilized AU-rich elements (ARE) within the 3' untranslated region (UTR) of target mRNAs. This mechanism is designed to selectively destabilize and downregulate transcripts of the TEAD1 and YAP1 genes, which are key components of the Hippo signaling pathway involved in cell proliferation and tissue homeostasis. The lead program is focused on Triple-Negative Breast Cancer (TNBC), particularly in African women, where TEAD1/YAP1 dysregulation is a significant driver. The drug is also in preclinical development for metabolic and liver conditions, including non-alcoholic steatohepatitis (NASH/MASH), alcoholic liver disease (ALD), and obesity.